N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
AssigneeSierra Oncology, Inc.
InventorsBrandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin
Life of this patent
Estimating the term…
Abstract
The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
Claims62
A compound selected from the group consisting of:
- N-(cyanomethyl)-4-(2-(4-morpholinoohenylamino)pyrimidin-4-yl)benzamide dihydrochloride monohydrate Form II;
- N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrirnidin-4-yl)benzarnide monohydrochloride anhydrous Form I;
- and
- N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide monohydrochloride anhydrous Form III.
A pharmaceutical composition comprising a compound having the formula
- or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or diluent;
- wherein one or more hydrogen atoms attached to carbon atoms of the compound are replaced by a deuterium atom.
A pharmaceutical composition comprising a compound having the formula
- or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or diluent;
- wherein one or more hydrogen atoms attached to carbon atoms of the compound are replaced by deuterium atoms.
A pharmaceutical composition comprising a compound having the formula
- or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or diluent;
- wherein one or more hydrogen atoms attached to carbon atoms of the compound are replaced by deuterium atoms.
A compound selected from the group consisting of:
- N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide dihydrochloride monohydrate Form II;
- N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide monohydrochloride anhydrous Form I;
- and
- N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide monohydrochloride anhydrous Form III;
- wherein one or more hydrogen atoms attached to carbon atoms of the compound are replaced by deuterium atoms.
A method for the treatment of a disease associated with Janus Kinase (JAK) which comprises administering to a subject in need thereof:
- an effective amount of a therapeutic agent that inhibits or modulates the activity of a bromodomain-containing protein;
- and
- an effective amount of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino) pyrimidin-4-yl)benzamide dihydrochloride monohydrate Form II.
Dependencies are inferred from the claim text.